Acne. Acne vulgaris
Conditions
Interventions
Intervention 1: Intervention group: Treatment with Montelukast 5 mg chewable tablet, once a day plus tertinoin 0.25% +and clindamycin topical cream (acnomis) applied to the whole face once a day for 3
Treatment - Drugs
Intervention group: Treatment with Montelukast 5 mg chewable tablet, once a day plus tertinoin 0.25% +and clindamycin topical cream (acnomis) applied to the whole face once a day for 3 months.
Control group: Treatment with placebo chewable tablet once a day plus tertinoin 0.25% +and clindamycin topical cream (acnomis) applied to the whole face once a day for 3 months.
Sponsors
Vice Chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with acne; being at the age of 15-45 years old; using antibiotic and other acne treatments for less than 3 months. Exclusion criteria: age under 14 year-old and older than 45 year-old; indication for systemic retinoid treatment; nodulocystic acne (with scar formation possibility); antibiotic treatment for more than 3 months; Hormonal related acne(polycystic ovarian disease)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acne severity. Timepoint: Before treatment, 1 month and 3 months after treatment. Method of measurement: Acne global severity scale questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug Side effects. Timepoint: 1 month and 3 months after the begining of treatment. Method of measurement: Asking patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamane Moghanlou
Razi skin hospital
Outcome results
None listed